Evaluation of HIF-1 inhibitors as anticancer agents

Research output: Contribution to journalReview articlepeer-review

Abstract

Hypoxia-inducible factor 1 (HIF-1) regulates the transcription of many genes involved in key aspects of cancer biology, including immortalization, maintenance of stem cell pools, cellular dedifferentiation, genetic instability, vascularization, metabolic reprogramming, autocrine growth factor signaling, invasion/metastasis, and treatment failure. In animal models, HIF-1 overexpression is associated with increased tumor growth, vascularization, and metastasis, whereas HIF-1 loss-of-function has the opposite effect, thus validating HIF-1 as a target. In further support of this conclusion, immunohistochemical detection of HIF-1α overexpression in biopsy sections is a prognostic factor in many cancers. A growing number of novel anticancer agents have been shown to inhibit HIF-1 through a variety of molecular mechanisms. Determining which combination of drugs to administer to any given patient remains a major obstacle to improving cancer treatment outcomes.

Original languageEnglish (US)
Pages (from-to)853-859
Number of pages7
JournalDrug Discovery Today
Volume12
Issue number19-20
DOIs
StatePublished - Oct 2007

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Fingerprint Dive into the research topics of 'Evaluation of HIF-1 inhibitors as anticancer agents'. Together they form a unique fingerprint.

Cite this